Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Bristol Myers Squibb, Constellation Pharmaceuticals, Inc, Incyte Corporation, and PharmaEssentia USA.

Community Practice Connections™: Individualizing Treatment Plans and Optimizing Outcomes for Patients With MF and PV: Stories Behind the Science

Release Date: January 19, 2021
Expiration Date: January 19, 2022

Activity Overview

Myeloproliferative neoplasms (MPNs) like polycythemia vera (PV) and myelofibrosis (MF) are hematologic malignancies that require careful monitoring and treatment. The goals of clinical management for patients include reduction of symptom burden and prevention of disease progression. In recent years, the discovery of mutations in the JAK2 and CALR genes has enabled a paradigm shift toward individualized risk stratification and treatment.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 62nd American Society of Hematology Annual Meeting & Exposition, held in December 2020. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects managing patients with MPNs including PV and MF, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learning for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb, Constellation Pharmaceuticals, Inc, Incyte Corporation, and PharmaEssentia USA.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, and other oncology health care professionals interested in the treatment of patients with MPNs. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of MPNs are invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Outline the latest discoveries in the pathophysiology of myelofibrosis (MF) and polycythemia vera (PV) and their potential impacts on clinical decision-making
Explain current clinical treatment strategies for patients with MF and PV
Summarize the latest data reported from ongoing clinical trials and their potential impacts on the treatment landscape of MF and PV
Develop a patient-specific plan to effectively monitor patients with MF and PV concerning treatment-related toxicities and management of disease-related symptoms

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Srdan Verstovsek, MD, PhD
United Energy Resources, Inc. Professor of Medicine
Chief, Section for Myeloproliferative Neoplasms (MPNs)
Director, Hanns A. Pielenz Clinical Research Center for MPNs
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Incyte Corporation, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma Corp., Genentech, Blueprint Medicines Corp., Novartis, Sierra Oncology, Pharma Essentia, Astrazeneca, Ital Pharma, Protagonist Therapeutics, Constellation Pharmaceuticals, Kartos Therapeutics, Prelude.

Claire Harrison, DM, FRCPath
Professor
Guy's and St Thomas' NHS Trust
London UK

Disclosures: Grant Research Support: Novartis, Celgene, Constellation; Consultant: Novartis, Roche, Celgene, BMS, Constellation, AOP, DISC, Promedior; Speakers Bureau: Novartis, Roche, Jannsen, AbbVie.

Ann Mullally, MD
Brigham and Women’s / Dana-Farber Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: Janssen, Actutate Therapeutics; Consultant: PharmaEssentia (Steering Committee), Constellation (Advisory Board), Relay Therapeutics.

Raajit K. Rampal, MD, PhD
Assistant Member
Clinical Director, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Incyte, Constellation, Stemline; Consultant: Incyte, Abbvie, Stemline, Disc Medicines, Celgene, Blueprint, CTI, Promedior, Galectco.

Alessandro Vannucchi, MD
Associate Professor of Hematology
University of Florence
Florence, Italy

Disclosures: Grant Research Support: Novartis, Incyte Corporation, Italfarmaco SpA, Bristol Myers Squibb, Constellation Pharmaceuticals; Consultant: Novartis, Celgene.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.